Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

Isogenica executes services agreement with J&JPRD

Isogenica Ltd today announced that it has executed a services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

22 Mar 2011

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire plc, the global specialty biopharmaceutical company, presented new data for Replagal in patients with Fabry disease, and VPRIV in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.

22 Mar 2011

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Data presented by CSL Behring today suggest that treatment with higher dose Hizentra correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies.

22 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix® (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC).

18 Mar 2011

Cangene second quarter revenues increase 3% to $40.2 million

Cangene Corporation today reports financial results for the quarter ended January 31, 2011, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

18 Mar 2011

APS ACTION brings experts together to improve patient outcomes

Motivated by the lack of treatment options for patients with antiphospholipid syndrome, rheumatology researchers convened an international committee to address the problem directly.

17 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Digna Biotech and Biotecnol announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I.

17 Mar 2011

Scientists to develop new universal vaccine against various flu viruses

A vaccine that helps against all types of influenza - for several years? If all goes right for Norwegian company Bionor Pharma ASA, such a vaccine could exist within a few years.

17 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.

16 Mar 2011

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.

16 Mar 2011

Ventana, CST enter license agreement for personalized cancer diagnostics

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.

From Cell Signaling Technology 16 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Antibody News and Research

Further Reading

SGEN, Abbott enter collaboration agreement for ADC products

Genetic errors in women linked to increased risk of preeclampsia

Isogenica executes services agreement with J&JPRD

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

CSL Behring presents Hizentra study data against PI at AAAAI meeting

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

EMA CHMP adopts negative opinion for Amgen's Vectibix in treatment of wild-type KRAS metastatic colorectal cancer

Cangene second quarter revenues increase 3% to $40.2 million

APS ACTION brings experts together to improve patient outcomes

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Scientists to develop new universal vaccine against various flu viruses

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Shanghai ChemPartner signs outsource research service agreement with Shenogen Pharma

Ventana, CST enter license agreement for personalized cancer diagnostics

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Millennium, SGEN expand ADC collaboration

Apeiron in antitumor substances deal with Cleveland Clinic

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Monoclonal Antibody Manufacturing Trends eBook eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News